Docro to Help ArrayIt with FDA Process for OvaDx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ArrayIt today said that it has signed an agreement with Docro to assist in its efforts to win US Food and Drug Administration clearance for its OvaDx test.

ArrayIt's OvaDx is a pre-symptomatic ovarian cancer test that includes 100 proteomic biomarkers in a microarray format. The Sunnyvale, Calif.-based firm said that the test can detect both early- and late-stage ovarian cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.